Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sure. Buying opportunity. Really? People can do what they want with their money. Can just burn it if they want. But everything is going to be all right. I know I feel better now. This company is turning into a joke with excuses more available than their product no one can find. But according to some, orders pending are huge and retailers are too numerous to count. Close your eyes. What do you see? NOTHING!
Just my opinion of course.
THE COMPANY AND OTIKO IS A F POS.BECAUSE IF HE WAS A GOOD CEO WOULD HAVE ADDRESSED IT RIGHT AWAY VIA PR TO HIS SHAREHOLDERS.BUT INSTEAD DID NOTHING.SO PEOPLE PANIC AND TAKING LOSSES.F YOU OTIKO.
The ongoing drop in share price has been triggered by an unbelievably careless error by otcmarkets. If regulation worked, WHICH IT DOES NOT, especially for small companies, all of the trades during the time period of the error would be cancelled, without mutual re-agreement of both parties.
If VDRM were an Accelerated Filer, meaning 2nd Qtr Report due 7/31/22. The four-day Grace Period, per Rule 15c2-11, will be between 8/1/22 - 8/4/22, i.e., NOT YET STARTED. However, VDRM is a non-Accelerated Filer, meaning 2nd Qtr Report due 8/15/22. Thus, the four-day Grace Period will be between 8/16/22 - 8/19/22. This is a significant mistake by otcmarkets. One can only wonder if it is systemwide and thus affecting more companies. May otcmarkets receive appropriate blowback.
https://www.wilmerhale.com/insights/client-alerts/20201029-sec-amends-rule-15c2-11-to-enhance-publicly-available-information-for-securities-quoted-in-the-over-the-counter-markets
$.00664 The VDRM Yield Sign/dark/defunct BS is a screw up on OTC Markets part. Being corrected!
$.0065 Just another VDRM buying opportunity. Things will be fine!
I JUST TWEETED THE PROBLEM FROM OTC TO OTIKO.
YOU NEED TO ADDRESS THIS ASAP. TO YOUR SHAREHOLDERS VIA PR.SERIOUS PROBLEM ON OTC.
— ORCA (@NBBLegend) July 27, 2022
CHECK LINK.SHAREHOLDERS ON IHUB ARE PISSED OFF ABOUT THIS PROBLEM.PLEASE ADDRESS IT.ASAP.
Grace Period IconGrace Period
Dark or Defunct IconDark or Defuncthttps://t.co/MbH4u1MScg
Yep.....News is once the Grace Period is up we hit the Expert Market where there will be no liquidity as it will not have any MM's.
Thanks for taking the time to do that. You never know...the Company may actually take notice.
For the board's information, I have emailed investor relations and otcmarkets about the issue. I do not expect response from investor relations since I have not received any response on over a year. Interestingly, I got a boilerplate response from otcmarkets:
As a market operator, our policy is not to comment on any specific company's status unless you are an officer or their legal counsel. You can contact the company directly regarding their Grace Period status.
My original message:
You are incorrectly tagging VDRM as Accelerated Filer which it is not. It is a Non-Accelerated Filer. Thus, your website is misleading in the Pink Limited Information.
The 2nd Quarter Report is not due to 8/15/22. Lastly, a grace period would be properly applied after a due date to get into compliance. Even if the nutty label is correct, the Grace Period label, being attached incorrectly since 8/15/22 -15 days is July 31, 2022.
I believe the OTC Market should be held liable for their mistake if they admit to making the mistake!!!
Rule 15c2-11 - It seems otcmarkets has carelessly messed up the whole thing relative to VDRM and that rule.
VDRM is Non-Accelerated Filer. Thus, 2nd Quarter Report is due 8/15/22, and not 7/31/22 for Accelerated Filer.
The Grace Period is 4 business days, not 15, and it is like every other grace period that I have ever heard of it, meaning that the grace period is AFTER a delinquency.
VDRM, and any other companies wrongly tagged, should issue letters to otcmarkets regarding the mistake, or take more aggressive action.
https://www.wilmerhale.com/insights/client-alerts/20201029-sec-amends-rule-15c2-11-to-enhance-publicly-available-information-for-securities-quoted-in-the-over-the-counter-markets
This company has revenues, profits, a proven and approved product and large orders to be filled. Based on comps with similar companies, many of whom have few or none of above, sp should be, at least, in the .40's, but probably won't be soon because of the quick flippers.
2022 has been setback after setback. Price has largely remained in the .006-.008 range despite all the negativity.
I’m here for the long haul. Not too concerned about this week or next, the expected news or filing status.
Sure does suck for the quick flippers though
Lol. Pretty sure there is no way out of the grace period. After 15 days.....expert market.....no liquidity etc
$.0076 Dr. Otiko will come through! VDRM will be fine, shortly!
Boom - thank you.
It appears to relate to the 2nd Quarter Report. It would appear that OTC does not have VDRM set correctly as Non-Accelerated Filer (8/15/22 due date (8/15/22 - 15 days = 7/31/22) versus 8/9/22 for Accelerated Filers (8/9/22 - 15 days = 7/25/22)). If you hover over Grace Period, it will give more information. However, in any event, this is still the first regulatory/financial type milestone, that I have encountered, that has a Grace Period leading up to the due date and not as attached additional period, after the due date.
The 2021 annual report was submitted on 3/29/2022. What was due/big event was around 180days ago?
Or wonder if VDRM notified OTCM of an amendment and that triggered the status. Hopefully find out soon
Thanks for the information.
I had never noticed those markings before on the OTC page or the additional information from hovering over them. I will say it is unexpected to have a grace period before a regulatory due date and not as additional time thereafter.
LMFAO.
15 Day Grace period BEFORE....
EXPERT MARKET
The amended rule adds a 15-day conditional grace period from the date of a publicly available determination that a company no longer has current information within the 180-day specified period as set forth in the chart below, for a broker-dealer to continue to quote the particular security. The purpose of the grace period is to give the markets notice that the company is in danger of no longer being quoted and provide investors with an opportunity to liquidate positions
I totally understand. Hopefully, it will become apparent soon and not be yet another setback!!!!
I am just posting as it shown. Maybe some of the previous filings are wrong…. Who knows/// It seems a very grave error by OTCM to make then. Got me off base to be honest tho
That seems like a mistake on OTC disclosure page ( https://www.otcmarkets.com/stock/VDRM/disclosure ). Otherwise, I am not sure what it could relate to. The 2022 2nd Quarter Report is not due until August 15th as Non-Accelerate Filer (https://www.skadden.com/-/media/files/publications/2021/12/2022-filing-deadlines/2022_sec_filing_deadlines_and_financial_statement_staleness_deadlines.pdf ).
VDRM: Grace Period Dark or Defunct Icon Dark or Defunct
My guess is as good as any so here goes. No news for another 6 weeks. The PR was extremely optimistic. The real world reality is much different. IMHO there will be delays in obtaining product for testing, delays due to vacations and COVID, delays due to questions relating to the results, possible rerunning of tests, delaying in writing the report, etc. Nothing like this ever happens quickly or within the prescribed time limits.
I hope I am wrong. I intend to consider the impending price dip (its gonna happen) as an additional opportunity to buy from impatient hands.
Good luck all.
I WAS BIDDING FOR 1,5 MILLION AT .007.I GOT ZERO SHARES.AND IT EXPIRED.
Expired Buy 1500000 VDRM Limit 0.007 -- 07/25/22 16:06:51 07/25/22
Order No. 9009269034 Viaderma, Inc. Common Sto...
Entered:13:09:04 07/25/22 Reuse
Big news coming this week!
Testing,etc.
DeerBalls I agree 100% & news very soon
It will or will not happen regardless of any great things type posts. Coming Soon.
$.008 No one is forced to buy/hold VDRM. Glad I bought away while it was down.
I have complete confidence in Dr. Otiko. Others may not and that is just fine!
Been holding stock in this company since Feb ‘17
Otiko has never come through on his promises. To say otherwise, you are living in fantasy land
After a call back he could not remember
will never waste my time listening to BS again
I Bad info from suppose to be good source
Yes and that's exactly what I was told
LET;S HOPE WE GET AN UPDATE FROM OTIKO.AND WE SHOULD.GOOD OR BAD.THE 4 WEEK MARK IS OVER OTIKO.
That's right! Update could be anyday next week!!!
I think if doc doesn't have news soon people should book appointment with him and put him on the spot because he has our money!!!!!!I If I lived with in 500 miles of his practice I would be there
He could be referring to you stating we just received 10k units on 6/14. Obvious bullsh*t
How about posting what you are referring to.
Let's just keep posting the release from June 22nd. Come on man enough. I would think most everyone here wants to see the big boom but posting unsubstantiated claims of orders being filled or retailers who will stock the products is just hearsay right now. I for one hope all these claims come true, but folks are way ahead of their skis at this point. IMO
Large orders being filled!
I bought a few more this week thinking Ok maybe something new will happen. Now I feel like I just through money away. I bought their product for my granddaughter over a year ago from Amazon and it really works but damn . . .
TODAY IS EXACTLY 4 WEEKS.OTIKO COME ON MAN.AT THE LEAST GIVE US AN UPDATE IF THERE IS A DELAY ETC.
Press Release | 06/22/2022
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
LOS ANGELES, June 22, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) announces plans to conduct additional internal quality control testing for their new Vitastem products. Vitastem and Vitastem Ultra are manufactured at a contract facility in the United States and have successfully undergone all standard testing required by regulators. Following extensive consultation with the Company’s manufacturing partners and potential purchasers and distributors of the products, the decision was made to implement further testing as an additional precautionary measure since both products are using new formulations.
The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs and are among the strongest and most effective topical antibiotics available on the market. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema). Vitastem Ultra uses bacitracin as the active ingredient and the new formula is clear and colorless compared to the brownish color of the original (which has tetracycline as the active ingredient), so it will not stain the skin, fingernails, toenails, or anywhere else it is applied. Both Vitastem and Vitastem Ultra work similarly and provide the same great results. The new formulation with bacitracin provides an alternative for consumers who are allergic or resistant to one or the other.
President and CEO, Dr. Chris Otiko said, “Since both of these products are a new and improved formulation, we decided now would be the best time to conduct additional testing before we begin large scale distribution.”
Dr. Otiko continued, “The products have tested well so far, and we expect they will continue to do so without issue, but because they are both different formulations than the original, and since we are moving much closer to having to fulfill large purchase orders, we felt we should implement these precautionary measures at this time in an abundance of caution. The last thing we want is to have a problem down the road when a correction would be much harder to address. Taking this step now will minimize the potential for such problems later.”
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
Followers
|
615
|
Posters
|
|
Posts (Today)
|
15
|
Posts (Total)
|
73875
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |